Less than 10% of individuals who could benefit from obesity jabs including Wegovy have access to them, caution the global health agency as it issues its inaugural guidance on the drugs.
Given more than one billion people worldwide now obese, it is urging increased and just availability to this class of drugs.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our new guidance acknowledges that excess weight is a long-term condition that can be treated with thorough and ongoing care," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major obstacles to broad availability to the injections that can assist patients in reducing substantial body mass, says the body.
Weight-Loss Drug Scarcity
Even under the current most favorable case, the production of these medications could only cover around 100 million people – fewer than 10% of eligible patients, as stated by the WHO.
The recommendation urges governments and firms to increase availability, through measures such as voluntary licensing.
Exclusive production rights on the active ingredient – the main ingredient of the drug Wegovy – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs imitate a biological compound to reduce digestion speed, curb appetite and increase satiety so people consume fewer calories.
Individuals commonly see weight reduction within a few weeks of commencing the regular doses.
Research indicates people may see weight return a year later of halting the drug, because their normal food cravings come back.
To be overweight or obese raises your likelihood for developing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight affects individuals in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the WHO.
